Mode
Text Size
Log in / Sign up
Phase 3 N=251 Randomized Quadruple-blind Treatment

Low Dose Aspirin for Venous Leg Ulcers

Venous Leg Ulcer

Enrolled (actual)
251
Serious AEs
8.4%
Results posted
Jan 2019
Primary outcome: Primary: Time to Complete Healing of Reference Ulcer — 77; 69 days — p=0.246

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Aspirin (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Auckland, New Zealand
Primary completion
Mar 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Complete Healing of Reference Ulcer
77; 69 0.246
SECONDARY
Number of Participants With Healed Venous Leg Ulcers
88; 101 0.073
SECONDARY
Change in Estimated Ulcer Area
4.1; 4.8 0.25
SECONDARY
Change in Health-related Quality of Life (Short Form 36)
5.0; 3.8; 11.7; 10.3; 11.4; 9.0 0.714
SECONDARY
Change in Health-related Quality of Life (EuroQol-5D 3L)
7.4; 4.0 0.156
SECONDARY
Change in Health-related Quality of Life (Charing Cross Venous Ulcer Questionnaire)
-6.2; -4.7; -6.6; -5.2; -6.1; -4.9 0.438
SECONDARY
Number of Participants With Adherence to Treatment
92; 92 0.917
SECONDARY
Incidence of Adverse Events at 24 Weeks
6; 1; 0; 4; 8; 4 0.71

Summary

Venous leg ulcers (VLU) are the most common leg ulcer, can be painful, and limit work, lifestyles and activity, especially in older patients. There are few effective treatments - compression therapy (tight bandaging or stockings) helps healing, but about half the people with a VLU remain unhealed even after 12 weeks of treatment. Research suggests taking aspirin as well as using compression may speed up healing for VLU, but the current evidence is not enough to change clinical practice. We will conduct a randomised controlled trial to test whether using low dose aspirin (150 mg daily or placebo) really does speed up healing.

Eligibility Criteria

Inclusion Criteria

  • Aged 18 years or older
  • Determined to have a venous leg ulcer (clinical indications of venous ulceration, Ankle Brachial Index ≥ 0.8, and other causative aetiologies ruled out)
  • Able to tolerate compression therapy
  • Able to provide written informed consent
  • Confirmation with participant's general practitioner that the participant can take low dose aspirin or placebo.

Exclusion Criteria

  • Pregnant or breast-feeding women
  • History of myocardial infarction, stroke, transient ischaemic attack, angina or significant peripheral arterial disease
  • History of adverse effects related to aspirin use
  • Currently using aspirin, or other anti-platelet or anticoagulant therapy
  • Opinion of screening medical practitioner at National Institute of Health Innovation that participant has an existing condition or treatment that is a contraindication to use of aspirin or to participation in the trial.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02158806). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search